14 / 39
OS by Prior Sunitinib and Prior Pazopanib Therapy in Patients With mRCC
HR (95% CI
), 0.81 (0.64–1.04)
Median OS, months
(95% CI)
Nivolumab
23.6 (20.4–28.1)
Everolimus
19.8 (17.5–24.3)
Prior sunitinib
HR (95% CI
), 0.60 (0.42–0.84)
Median OS, months
(95% CI)
Nivolumab
NE (19.7–NE)
Everolimus
17.6 (14.3–19.9)
Prior pazopanib
Based on data cut-off of June 2015.Motzer RJ et al. Oral presentation at ASCO GU 2016. 498
.
No. of patients at risk
Nivolumab
257
223
191
133
51
3
Everolimus
261
211
170
122
41
2
Overall Survival (Probability)
0
3
6
12
9
15
Months
18
21
24
27
30
33
Nivolumab
0.0
0.1
0.8
0.9
0.2
0.3
0.4
0.5
0.6
0.7
1.0
0
3
6
12
9
15
Months
18
21
24
27
30
33
Nivolumab
Everolimus
126
111
93
62
19
2
136
100
81
52
13
0
0.0
0.1
0.8
0.9
0.2
0.3
0.4
0.5
0.6
0.7
1.0
63%
49%
Everolimus
61%
54
%